Key Points
- CEO Brittany Kaiser bought 9,350 Portage Biotech shares at an average price of $5.35, investing $50,022.50 and increasing her direct ownership by 126.08% to 16,766 shares.
- Portage Biotech’s stock opened at $4.16, with a market capitalization of approximately $6.45 million, and traded well below its 50-day and 200-day moving averages.
- Analyst sentiment remains cautious: two analysts rate the stock “Hold” and one rates it “Sell,” producing a consensus “Reduce” rating and a $12.50 target price.
Portage Biotech Inc. (NASDAQ:ALP - Get Free Report) insider Fiorenzo Villani acquired 7,000 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were bought at an average cost of $5.07 per share, with a total value of $35,490.00. Following the completion of the acquisition, the insider owned 22,219 shares in the company, valued at approximately $112,650.33. This represents a 46.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Portage Biotech Price Performance
ALP stock opened at $4.16 on Tuesday. The company has a market capitalization of $6.45 million, a PE ratio of -0.51 and a beta of 0.54. Portage Biotech Inc. has a one year low of $3.20 and a one year high of $690.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.31 and a current ratio of 0.31. The company's fifty day moving average price is $10.53 and its 200-day moving average price is $14.74.
Portage Biotech (NASDAQ:ALP - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The company reported $23.75 EPS for the quarter. The company had revenue of $0.05 million for the quarter. On average, equities analysts anticipate that Portage Biotech Inc. will post -14 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on ALP shares. Zacks Research upgraded Portage Biotech to a "hold" rating in a report on Tuesday, August 18th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Portage Biotech in a research report on Friday, July 24th. Wall Street Zen raised shares of Portage Biotech to a "hold" rating in a report on Saturday. Finally, HC Wainwright started coverage on shares of Portage Biotech in a research note on Monday, August 17th. They set a "neutral" rating and a $12.50 price target on the stock. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Portage Biotech presently has a consensus rating of "Reduce" and a consensus target price of $12.50.
View Our Latest Analysis on Portage Biotech
Portage Biotech Company Profile
(
Get Free Report)
Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.
Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
